Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: A randomized, double-blind, placebo-controlled clinical trial.

@article{Kantartzis2018EffectsOR,
  title={Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: A randomized, double-blind, placebo-controlled clinical trial.},
  author={Konstantinos Kantartzis and Louise Fritsche and Maria Bombrich and J{\"u}rgen Machann and Fritz Schick and Harald Staiger and Iris Kunz and Rotraut Schoop and Angela Lehn-Stefan and Martin Heni and Andreas Peter and Andreas Fritsche and Hans-Ulrich H{\"a}ring and Norbert Stefan},
  journal={Diabetes, obesity & metabolism},
  year={2018},
  volume={20 7},
  pages={
          1793-1797
        }
}
We performed the largest randomized, placebo-controlled clinical trial to date (N = 112, 12-week intervention) to investigate the effects and safety of resveratrol supplementation on liver fat content and cardiometabolic risk parameters in overweight and obese and insulin-resistant subjects. At baseline the variability in liver fat content was very large… CONTINUE READING